Clinical Growth Rate of Acoustic Schwannomas: Correlation with the Growth Fraction as Defined by the Monoclonal Antibody Ki-67

Lesser, T. H. J.; Janzer, Robert C.; Kleihues, Paul; Fisch, Ugo

doi:10.1055/s-2008-1056973

Cited by 50 publications

(42 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using this new method MIB 1, we have recently demonstrated the results of 30 solitary vestibular schwannomas: the labelling index obtained was less than 1% in 21 cases, 1-3% in 7 cases, and more than 3% in 2 cases [1]. These results were comparable to other studies with Ki-67 and antiBUdR reported in the literature [2,5,6,12,15,18,22].…”

Section: Discussionsupporting

confidence: 91%

The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1

et al. 1995

View full text Add to dashboard Cite

Formalin-fixed paraffin sections of 55 consecutive bilateral vestibular schwannomas in 46 patients with neurofibromatosis 2 (NF2), and 50 patients with unilateral vestibular schwannomas were investigated immunohistochemically with the monoclonal antibody MIB 1 directed against recombinant parts of Ki-67 antigen. The immunohistochemical staining was carried out on dewaxed microwave oven-processed paraffin sections of formalin-fixed tumour tissues. The labelling index (LI) obtained was compared to clinical and histological findings in both groups. There was no correlation between the LI and age of the patients, tumour size, or histological type of tumour (Antoni A or B). Vestibular schwannomas in NF2 showed higher LI than unilateral vestibular schwannomas: the maximal LI found per section (LI max) ranged from 0.4 to 17.6% (mean, 2.7%) in NF2 schwannomas, and from 0 to 9% (mean, 2.2%) in unilateral schwannomas. These differences may express immunohistochemically some clinical and morphological differences between bilateral and unilateral vestibular schwannomas.

show abstract

Section: Discussionsupporting

confidence: 91%

The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1

et al. 1995

View full text Add to dashboard Cite

show abstract

“…In a previous study, large VS exhibited enhanced proliferative activity compared with smaller lesions [28]. Similar results have also been reported by other authors describing a higher proliferative activity in large tumors [29,30,31]. However, these results have been contradicted by Charabi et al [32,33], who found no correlation between tumor size and proliferative activity.…”

Section: Discussioncontrasting

confidence: 46%

The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence

Koutsimpelas

Bjelopavlovic²,

Yetis³

et al. 2012

ORL

View full text Add to dashboard Cite

Background/Aims: The molecular mechanisms downstream of mutated neurofibromatosis type 2 (NF2) gene resulting in the growth and development of vestibular schwannoma (VS) are controversial. Several lines of evidence suggest the involvement of the vascular endothelial growth factor (VEGF) pathway in VS development. Given that recent studies of VEGF blockade in patients with NF2-associated VS showed positive effects on VS growth control, we initiated this comprehensive study of the VEGF pathway in sporadic VS. Methods: A tissue microarray analysis of 182 sporadic VS was conducted. The expression of VEGF and its receptors as well as the proliferative activity of the tumors were quantified. The expression data were correlated to tumor volumes and diameters as well as to tumor recurrence and previous irradiation. Results: All studied tumors expressed VEGF and its receptors. Proliferative activity was related to the growth characteristics of the tumors. Moreover, we found significantly higher VEGF levels in recurrent tumors(p = 0.0387) and in preoperatively irradiated tumors (p = 0.0213). Conclusion: Our data suggest a relevant role of the VEGF pathway in VS growth and therapy outcome. Therefore, targeting this pathway using antiangiogenic compounds might be beneficial for patients with sporadic VS, especially those with recurrent or irradiated tumors.

show abstract

“…In fact, the tumour growth demonstrated by radiography, does not necessarily represent tumour cell proliferation, as factors other than actual cellular turnover rate influence the size of neurilemomas. The tumour volume may be affected by cell death, intratumoural haemorrhage, cystic degeneration and scarring [6,7]. Beside this, neurilemomas with larger volume may have more cells resting in the postmitotic G0-phase (quiescent phase).…”

Section: Discussionmentioning

confidence: 99%

“…Most of these studies have used radiological methods [7]. The immunohistochemical studies allow immediate and accurate determination of the tumour growth potential [6,15]. The cell kinetics of the neurilemomas can be studied in paraffin sections with the help of MIB 1 testing, which has same sensitivity and specificity of Ki-67.…”

Section: Discussionmentioning

confidence: 99%

Proliferative activity of acoustic neurilemomas without neurofibromatosis determined by monoclonal antibody MIB 1

et al. 1995

View full text Add to dashboard Cite

Microscopic sections obtained from paraffin blocks of 30 consecutive neurilemomas stored in 1989 were investigated immunohistochemically with the new monoclonal antibody MIB 1 directed against recombinant parts of Ki-67 antigen. The immunohistochemical staining was carried out on dewaxed microwave-oven-processed paraffin sections of formalin-fixed tumour tissues. The labelling index (LI) obtained was below 1% in 21 cases, 1-3% in 7 cases and more than 3% in 2 cases. There was no correlation between the LI and the age of the patients or the tumour size. The major advantage of MIB 1 over previous immunohistochemical methods is its usefulness in long preserved sections which are ideal for retrospective studies.

show abstract

Clinical Growth Rate of Acoustic Schwannomas: Correlation with the Growth Fraction as Defined by the Monoclonal Antibody Ki-67

Cited by 50 publications

References 22 publications

The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1

The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1

The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence

Proliferative activity of acoustic neurilemomas without neurofibromatosis determined by monoclonal antibody MIB 1

Contact Info

Product

Resources

About